TerminatedNot Applicable

Randomized, Split-body, Single-blinded Clinical Trial of NB-UVB Treatment for Vitiligo

Stopped: Lack of enrollment and staff availability to administer treatment.

United States2 participantsStarted 2015-07

Plain-language summary

The objective of this study is to assess the effectiveness and safety of narrowband-ultraviolet B (NB-UVB) treatment in adult subjects with vitiligo.

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

✓. postmenopausal, defined as 45 years of age with amenorrhea for at least 18 months, or \>45 years of age with amenorrhea for at least 6 months and a serum follicule stimulating hormone (FSH) level \>40 IU/mL, or surgically postmenopausal (bilateral oophorectomy), or
✓. surgically sterile (have had a hysterectomy or tubal ligation or otherwise be incapable of pregnancy), or
✓. If heterosexually active and of childbearing potential, practicing a highly effective method of birth control, (examples include hormonal prescription oral contraceptives, contraceptive injections, contraceptive patch, intrauterine device, double-barrier method (e.g. condoms, diaphragms, or cervical cap, with spermicidal foam, cream, or gel), or male partner sterilization consistent with local regulations regarding the use of birth control methods for subjects participating in clinical trials, for the duration of their participation in the study, or
✓. Not heterosexually active

Vitiligo Area Scoring Index (VASI)

Timeframe: 24 weeks

NCT IDNCT02506101

SponsorJohns Hopkins University

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2016-10-04

Results submitted2017-08-30